ArticleFrontiers in oncology2022

Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon

Lanzi Ou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.